IMMUNOCORE HOLDINGS PLC

(IMCR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Putting Up Modest Gains

01/26/2022 | 01:28pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AUSTRALIAN DOLLAR / US DOLLAR (AUD/USD) -0.13% 0.7032 Delayed Quote.-3.01%
BRITISH POUND / US DOLLAR (GBP/USD) 0.19% 1.24866 Delayed Quote.-7.89%
CANADIAN DOLLAR / US DOLLAR (CAD/USD) -0.17% 0.7783 Delayed Quote.-1.43%
EURO / US DOLLAR (EUR/USD) -0.11% 1.0548 Delayed Quote.-6.97%
HEPION PHARMACEUTICALS, INC. 0.11% 0.7458 Delayed Quote.-34.58%
IMMUNOCORE HOLDINGS PLC 3.99% 30.21 Delayed Quote.-11.77%
INDIAN RUPEE / US DOLLAR (INR/USD) -0.59% 0.012844 Delayed Quote.-3.79%
NASDAQ COMP. -0.30% 11354.62 Real-time Quote.-27.42%
NEW ZEALAND DOLLAR / US DOLLAR (NZD/USD) 0.38% 0.64048 Delayed Quote.-6.67%
TYME TECHNOLOGIES, INC. 0.66% 0.274 Delayed Quote.-54.57%
All news about IMMUNOCORE HOLDINGS PLC
05/11Immunocore Holdings Q1 Net Loss Narrows as Revenue Rises
MT
05/11Immunocore Holdings plc Reports Earnings Results for the First Quarter Ended March 31, ..
CI
05/11Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
GL
04/18IMMUNOCORE : Corporate Presentation - April 2022
PU
04/07Immunocore to present at the 21st Annual Needham Healthcare Conference
AQ
04/04IMMUNOCORE : European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unr..
PU
04/04Immunocore Wins European Regulatory Ok of Kimmtrak for Unresectable or Metastatic Uveal..
MT
04/04European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable ..
GL
04/04European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable ..
GL
04/04European Commission Approves Immunocore Holdings plc's KIMMTRAK (Tebentafusp) for the T..
CI
More news
Analyst Recommendations on IMMUNOCORE HOLDINGS PLC
More recommendations
Financials
Sales 2022 83,5 M 104 M 104 M
Net income 2022 -89,2 M -111 M -111 M
Net cash 2022 226 M 282 M 282 M
P/E ratio 2022 -12,3x
Yield 2022 -
Capitalization 1 064 M 1 326 M 1 326 M
EV / Sales 2022 10,0x
EV / Sales 2023 11,3x
Nbr of Employees 324
Free-Float 37,6%
Chart IMMUNOCORE HOLDINGS PLC
Duration : Period :
Immunocore Holdings plc Technical Analysis Chart | IMCR | US45258D1054 | MarketScreener
Technical analysis trends IMMUNOCORE HOLDINGS PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2 423,60 GBX
Average target price 4 291,74 GBX
Spread / Average Target 77,1%
EPS Revisions
Managers and Directors
Bahija Jallal Chief Executive Officer & Director
Brian R. DiDonato Chief Financial Officer & Head-Strategy
John Irving Bell Chairman
David Berman Head-Research & Development
Travis Coy Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUNOCORE HOLDINGS PLC-11.77%1 326
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567